Incidence and evolution of venous thrombosis during the first 3 months after irreversible electroporation of malignant hepatic tumours.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 12 2019
27 12 2019
Historique:
received:
28
06
2019
accepted:
09
12
2019
entrez:
29
12
2019
pubmed:
29
12
2019
medline:
11
11
2020
Statut:
epublish
Résumé
The incidence and evolution of venous thrombosis adjacent to the ablation zone after percutaneous irreversible electroporation (IRE) were evaluated to identify potential risk factors in patients with hepatic malignancies. 205 venous structures (in 87 patients) within a ≤1.0 cm radius of the ablation zone were assessed after IRE of 112 hepatic lesions (74 primary, 38 secondary hepatic malignancies) by pre-interventional and post-interventional (1-3 days, 6 weeks and 3 months after IRE) contrast-enhanced magnetic resonance imaging. The relationships between venous thrombosis and clinical features were analysed using a binary logistic regression model. In 27 of 87 patients (31%), a total of 67 venous complications were noted during the 3 months follow-up. Thrombosis represented the most frequently observed complication (n = 47; 70.1%), followed by vessel narrowing (n = 20; 29.9%). 5 (10.6%) of 47 thromboses showed spontaneous regression 3 months after IRE. A small vessel diameter (p = 0.011) and post-interventional vessel narrowing (p = 0.006) were independently associated with delayed post-ablative thrombosis. Delayed venous thrombosis frequently occurs after IRE of hepatic malignancies. Pre-existing vessel narrowing and a small vessel diameter represent significant risk factors that require further surveillance and potentially therapeutic intervention.
Identifiants
pubmed: 31882716
doi: 10.1038/s41598-019-56324-y
pii: 10.1038/s41598-019-56324-y
pmc: PMC6934799
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
19876Références
Radiology. 2012 Jan;262(1):117-25
pubmed: 22106355
Radiol Oncol. 2019 Mar 3;53(1):116-122
pubmed: 30840591
Sci Rep. 2019 Feb 25;9(1):2647
pubmed: 30804395
J Vasc Interv Radiol. 2011 Jul;22(7):947-51
pubmed: 21550820
Sci Rep. 2019 Mar 6;9(1):3649
pubmed: 30842517
PLoS One. 2015 Aug 13;10(8):e0135773
pubmed: 26270651
Technol Cancer Res Treat. 2007 Feb;6(1):37-48
pubmed: 17241099
Invest Radiol. 2012 Nov;47(11):671-5
pubmed: 23037001
Biomed Eng Online. 2014 Mar 12;13(1):29
pubmed: 24621079
J Vasc Interv Radiol. 2014 Nov;25(11):1706-8
pubmed: 25442133
J Comput Assist Tomogr. 2013 Mar-Apr;37(2):154-8
pubmed: 23493202
Radiology. 2010 May;255(2):426-33
pubmed: 20413755
Semin Oncol. 2002 Apr;29(2):107-18
pubmed: 11951208
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818785329
pubmed: 29986632
Cardiovasc Intervent Radiol. 2010 Feb;33(1):11-7
pubmed: 19924474
Radiology. 2017 Dec;285(3):1023-1031
pubmed: 28799842
Radiology. 2014 Mar;270(3):888-99
pubmed: 24475820
Hepatology. 2006 May;43(5):1101-8
pubmed: 16628706
Nat Rev Cancer. 2014 Mar;14(3):199-208
pubmed: 24561446
Cardiovasc Intervent Radiol. 2014 Dec;37(6):1523-9
pubmed: 25212418